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ABSTRACT
This consensus document is intended to serve 3 functions. First, it standardizes the criteria for diagnosis of
chronic graft-versus-host disease (GVHD). Second, it proposes a new clinical scoring system (0-3) that
describes the extent and severity of chronic GVHD for each organ or site at any given time, taking functional
impact into account. Third, it proposes new guidelines for global assessment of chronic GVHD severity that
are based on the number of organs or sites involved and the degree of involvement in affected organs (mild,
moderate, or severe). Diagnosis of chronic GVHD requires the presence of at least 1 diagnostic clinical sign
of chronic GVHD (e.g., poikiloderma or esophageal web) or the presence of at least 1 distinctive manifestation
(e.g., keratoconjunctivitis sicca) confirmed by pertinent biopsy or other relevant tests (e.g., Schirmer test) in
the same or another organ. Furthermore, other possible diagnoses for clinical symptoms must be excluded. No
time limit is set for the diagnosis of chronic GVHD. The Working Group recognized 2 main categories of
GVHD, each with 2 subcategories. The acute GVHD category is defined in the absence of diagnostic or
distinctive features of chronic GVHD and includes (1) classic acute GVHD occurring within 100 days after
transplantation and (2) persistent, recurrent, or late acute GVHD (features of acute GVHD occurring beyond
100 days, often during withdrawal of immune suppression). The broad category of chronic GVHD includes (1)
classic chronic GVHD (without features or characteristics of acute GVHD) and (2) an overlap syndrome in
which diagnostic or distinctive features of chronic GVHD and acute GVHD appear together. It is currently
recommended that systemic therapy be considered for patients who meet criteria for chronic GVHD of
moderate to severe global severity.
© 2005 American Society for Blood and Marrow Transplantation
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DACKGROUND
Chronic graft-versus-host disease (GVHD) is a
ajor complication of allogeneic hematopoietic cell
ransplantation (HCT). The syndrome has features
esembling autoimmune and other immunologic dis-
rders such as scleroderma, Sjögren syndrome, pri-
ary biliary cirrhosis, wasting syndrome, bronchiolitis
bliterans (BO), immune cytopenias, and chronic im-
unodeﬁciency. The pathogenesis of chronic GVHD
s poorly understood [1].
Symptoms usually present within 3 years after
llogeneic HCT and are often preceded by a history of
cute GVHD. Manifestations of chronic GVHD may
e restricted to a single organ or tissue or may be
idespread. Chronic GVHD can lead to debilitating
onsequences, e.g., joint contractures, loss of sight,
nd-stage lung disease, or mortality resulting from
rofound chronic immune suppression leading to re-
urrent or life-threatening infections. Historically,
hronic GVHD was classiﬁed as limited or extensive
n the basis of the results of a small retrospective study
2], although this classiﬁcation has not been shown to
e reproducible or predictive of late treatment-related
ortality (TRM).
Reported incidence rates of chronic GVHD after
llogeneic transplantation range from 6% to 80% ac-
ording to recipient age, donor type, HCT source
peripheral blood, bone marrow, or umbilical cord
lood stem cells), graft manipulation (T-cell deple-
ion), and use of posttransplantation donor lympho-
yte infusions (DLIs) [3-5]. Reliable incidence esti-
ates in different cohorts of HCT recipients are
ompromised by (1) lack of standardized, widely used
iagnostic guidelines; (2) variability in observer expe-
ience; (3) limited expert follow-up at a distance from
ransplant centers; (4) differences in the statistical
ethods applied (e.g., use of the Kaplan-Meier versus
umulative incidence estimates and variable require-
ent for some minimal survival [60-100 days] for
atients to be considered at risk of chronic GVHD);
nd (5) the sometimes protean nature of early chronic
VHD symptoms, which mimic alternative diag-
oses. Previous articles have identiﬁed risk factors for
hronic GVHD after HCT, including prior acute
VHD, older patient age, the use of female donors
or male recipients, use of DLI, use of unrelated or
LA-mismatched donors, and, more recently, the use
f growth factor–mobilized peripheral blood leuko-
he opinions expressed here are those of the authors and do not represent
he ofﬁcial position of the National Institutes of Health or the US Gov-prnment.
46ytes as opposed to marrow as a source of stem cells
6-18].
URPOSE OF THIS DOCUMENT
The goals of this consensus document are to es-
ablish standardized criteria for the diagnosis of
hronic GVHD and to propose tools for scoring
hronic GVHD organ involvement and assessing
verall severity. Speciﬁcally, the Working Group
ought to (1) develop minimal criteria for the clinical
iagnosis of chronic GVHD; (2) propose a new scor-
ng system that describes the extent and severity of
hronic GVHD for each organ or site at any given
ime, taking functional impact into account; (3) pro-
ose new guidelines for global assessment of chronic
VHD severity; and (4) propose indications for top-
cal or systemic therapies.
The recommendations of the Working Group
epresent a consensus opinion supplemented by eval-
ation of available peer-reviewed literature. The pro-
osed methods and tools for diagnosis and scoring of
hronic GVHD are provisional and will be updated
ccording to the results of prospective validation stud-
es.
UMMARY OF RECOMMENDATIONS
The diagnosis of chronic GVHD requires the fol-
owing:
1. Distinction from acute GVHD.
2. Presence of at least 1 diagnostic clinical sign of
chronic GVHD or presence of at least 1 distinc-
tive manifestation conﬁrmed by pertinent bi-
opsy or other relevant tests.
3. Exclusion of other possible diagnoses.
Scoring of organ manifestations requires careful
ssessment of signs, symptoms, laboratory values, and
ther study results.
A clinical scoring system (0-3) is provided for
valuation of the involvement of individual organs and
ites.
The proposed global assessment of severity (mild,
oderate, or severe) is derived by combining organ-
nd site-speciﬁc scores.
Systemic therapy should be considered for pa-
ients who meet criteria for moderate to severe global
everity.
IAGNOSIS OF CHRONIC GVHD
In the past, any manifestation of GVHD that was
resent (or continued) at 100 days after HCT or
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Diagnosis and Staging of Chronic Graft-versus-Host Disease
Bhereafter was arbitrarily deﬁned as chronic GVHD
ven if the clinical manifestation was indistinguishable
rom that of acute GVHD. Advances in HCT practice
n the past 2 decades have profoundly altered the
resentation and natural history of both acute and
hronic GVHD and bring previous deﬁnitions into
uestion. For instance, acute GVHD may present
eyond 3 months in patients who have received re-
uced-intensity conditioning [19,20], whereas mani-
estations of acute and chronic GVHD can be present
imultaneously, for example, in patients treated with
LI. Therefore, the current consensus is that clinical
anifestations, and not the time to symptomatic onset
fter transplantation, determine whether the clinical
yndrome of GVHD is considered acute or chronic.
Throughout this article, diagnostic signs and symp-
oms refer to those manifestations that establish the
resence of chronic GVHD without the need for
urther testing or evidence of other organ involve-
ent. Distinctive signs and symptoms of chronic
VHD refer to those manifestations that are not
rdinarily found in acute GVHD but are not consid-
red sufﬁcient to establish an unequivocal diagnosis of
hronic GVHD without further testing or additional
rgan involvement. Other features of chronic GVHD
eﬁne the rare, controversial, or nonspeciﬁc features
f chronic GVHD that cannot be used to establish the
iagnosis of chronic GVHD. Common signs and symp-
oms of chronic GVHD refer to manifestations found
n both chronic and acute GVHD (Table 1).
The Working Group recommends that the diag-
osis of chronic GVHD require at least 1 diagnostic
anifestation of chronic GVHD or at least 1 distinc-
ive manifestation, with the diagnosis conﬁrmed by
ertinent biopsy, laboratory tests, or radiology in the
ame or another organ. As in acute GVHD, infection
nd other causes may confound or complicate the
ifferential diagnosis of chronic GVHD (e.g., nail
ystrophies associated with onychomycosis, herpes
implex, or Candida albicans infections of the oral cav-
ty; drug toxicity) and must be excluded. Diagnostic
nd distinctive manifestations of chronic GVHD can
e found in the skin and appendages, mouth, eyes,
emale genitalia, esophagus, lungs, and connective tis-
ues. Biopsy or other testing is always encouraged and
ften valuable to conﬁrm the presence of chronic
VHD, but it is not always feasible and is not man-
atory if the patient has at least 1 of the diagnostic
ndings of chronic GVHD (Table 1). Please note that
n in-depth discussion of recommended terminology
or histopathologic interpretation may be found in a
orthcoming histopathology working group report. A
iopsy read as “consistent with” or “unequivocal”
hronic GVHD will be considered sufﬁcient to estab-
ish the diagnosis of chronic GVHD if accompanied
y at least 1 distinctive clinical manifestation.Characteristics that establish the diagnosis of n
B&MThronic GVHD might not serve as the most appro-
riate parameters for assessing the severity of chronic
VHD. Valid and reliable diagnostic criteria might
ot be sufﬁciently sensitive to change to be useful as
reatment-response criteria. Conversely, a sensitive
easure of chronic GVHD response might not nec-
ssarily serve as an appropriate diagnostic and scoring
ool.
RGAN-SPECIFIC MANIFESTATIONS OF CHRONIC
VHD
In all cases, drug reaction, infection, recurrent or
ew malignancy, and other causes must be excluded.
iagnostic clinical or laboratory features sufﬁcient for
he diagnosis of chronic GVHD are italicized in the
ections below.
kin
Diagnostic manifestations include poikiloderma
e.g., atrophic and pigmentary changes), lichen planus-
ike eruption (e.g., erythematous/violaceous ﬂat-topped
apules or plaques with or without surface reticula-
ions or a silvery or shiny appearance on direct light),
eep sclerotic features (e.g., smooth, waxy, indurated
kin—“thickened or tight skin,” caused by deep and
iffuse sclerosis over a wide area), morphea-like super-
cial sclerotic features (e.g., localized patchy areas of
oveable smooth or shiny skin with a leathery-like
onsistency, often with dyspigmentation), or lichen
clerosus-like lesions (e.g., discrete to coalescent gray to
hite moveable papules or plaques, often with follic-
lar plugs, with a shiny appearance and leathery con-
istency). Severe sclerotic features characterized by
hickened, tight, and fragile skin are often associated
ith poor wound healing, inadequate lymphatic drain-
ge, and skin ulcers from minor trauma.
A distinctive feature for chronic GVHD (not seen
n acute GVHD, but not sufﬁciently unique to be
onsidered diagnostic of chronic GVHD) is depig-
entation. However, depigmentation would contrib-
te to the diagnosis of chronic GVHD in combination
ith biopsy or laboratory conﬁrmation of GVHD in
kin or another organ. Sweat impairment and intoler-
nce to temperature change from loss of sweat glands
re seen in chronic GVHD. Other common, nondis-
inctive skin manifestations found with both acute and
hronic GVHD include erythema, maculopapular
ash, and pruritus.
ails
Dystrophy consisting of longitudinal ridging, nail
plitting or brittleness, onycholysis, pterygium unguis,
nd nail loss (usually symmetric and affecting most
ails) are distinctive signs of chronic GVHD but are
ot sufﬁcient for diagnosis.
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9able 1. Signs and Symptoms of Chronic GVHD
Organ or Site
Diagnostic (Sufficient to
Establish the Diagnosis of
Chronic GVHD)
Distinctive (Seen in Chronic GVHD, but
Insufficient Alone to Establish a
Diagnosis of Chronic GVHD) Other Features*
Common (Seen with
Both Acute and
Chronic GVHD)
kin Poikiloderma Depigmentation Sweat impairment Erythema
Lichen planus-like features Ichthyosis Maculopapular rash
Sclerotic features Keratosis pilaris Pruritus
Morphea-like features Hypopigmentation
Lichen sclerosus-like features Hyperpigmentation
ails Dystrophy
Longitudinal ridging, splitting, or brittle
features
Onycholysis
Pterygium unguis
Nail loss (usually symmetric; affects
most nails)†
calp and
body hair
New onset of scarring or nonscarring
scalp alopecia (after recovery from
chemoradiotherapy)
Scaling, papulosquamous lesions
Thinning scalp
hair, typically
patchy, coarse,
or dull (not
explained by
endocrine or
other causes)
Premature gray
hair
outh Lichen-type features Xerostomia Gingivitis
Hyperkeratotic plaques Mucocele Mucositis
Restriction of mouth
opening from sclerosis
Mucosal atrophy
Pseudomembranes†
Ulcers†
Erythema
Pain
yes New onset dry, gritty, or painful eyes‡ Photophobia
Cicatricial conjunctivitis
Keratoconjunctivitis sicca‡
Confluent areas of punctate keratopathy
Periorbital
hyperpigmentation
Blepharitis
(erythema of
the eyelids with
edema)
enitalia Lichen planus-like features Erosions†
Vaginal scarring or stenosis Fissures†
Ulcers†
I tract Esophageal web
Strictures or stenosis in the
upper to mid third of the
esophagus†
Exocrine
pancreatic
insufficiency
Anorexia
Nausea
Vomiting
Diarrhea
Weight loss
Failure to thrive
(infants and children)
iver Total bilirubin, alkaline
phosphatase >2 
upper limit of
normal†
ALT or AST >2 
upper limit of
normal†
ung Bronchiolitis obliterans
diagnosed with lung biopsy
Bronchiolitis obliterans diagnosed with
PFTs and radiology‡
BOOP
uscles,
fascia,
joints
Fasciitis
Joint stiffness or
contractures secondary to
Myositis or polymyositis‡ Edema
Muscle cramps
Arthralgia orsclerosis arthritis
48
Hn
r
o
G
t
M
c
a
a
d
f
G
c
t
a
c
g
E
c
c
ﬂ
i
d
o
e
l
e
c
m
s
c
o
G
p
a
G
t
d
g
c
w
m
o
d
n
T
H
O
G
*
†
‡ ation
Diagnosis and Staging of Chronic Graft-versus-Host Disease
Bair
Distinctive features of chronic GVHD include
ew scarring and nonscarring scalp alopecia (after
ecovery from chemotherapy or radiotherapy) and loss
f body hair. Other characteristics seen with chronic
VHD include premature graying, thinning, or brit-
leness, but these ﬁndings are not diagnostic.
outh
Diagnostic features of oral chronic GVHD in-
lude lichen planus-like changes (white lines and lacy-
ppearing lesions of the buccal mucosa, tongue, pal-
te, or lips), hyperkeratotic plaques (leukoplakia), or
ecreased oral range of motion in patients with sclerotic
eatures of skin GVHD. Distinctive features of chronic
VHD include xerostomia (dryness), mucoceles, mu-
osal atrophy, pseudomembranes, and ulcers (infec-
ious pathogens such as yeast or herpesvirus; second-
ry malignancy must be excluded). Manifestations
ommon to both acute and chronic GVHD include
ingivitis, mucositis, erythema, and pain.
yes
Distinctive manifestations of chronic GVHD in-
lude new onset of dry, gritty, or painful eyes; cicatri-
ial conjunctivitis; keratoconjunctivitis sicca; and con-
uent areas of punctate keratopathy. Other features
able 1. Continued
Organ or
Site
Diagnostic
(Sufficient to Establish the
Diagnosis of Chronic GVHD)
D
(Seen in Chronic
Alone
Diagnosis o
ematopoietic
and
immune
ther
VHD indicates graft-versus-host disease; ALT, alanine aminotran
organizing pneumonia; PFTs, pulmonary function tests; AIH
purpura.
Can be acknowledged as part of the chronic GVHD symptomato
In all cases, infection, drug effects, malignancy, or other causes m
Diagnosis of chronic GVHD requires biopsy or radiology conﬁrmnclude photophobia, periorbital hyperpigmentation, t
B&MTifﬁculty in opening the eyes in the morning because
f mucoid secretions, and blepharitis (erythema of the
ye lids with edema). New ocular sicca documented by
ow Schirmer test values with a mean value of both
yes 5 mm at 5 minutes or a new onset of kerato-
onjunctivitis sicca by slit-lamp examination with
ean values of 6 to 10 mm on the Schirmer test is
ufﬁcient for the diagnosis of chronic GVHD if ac-
ompanied by distinctive manifestations in at least 1
ther organ.
enitalia
Diagnostic features for the genitalia include lichen
lanus-like features and vaginal scarring or stenosis (often
ssociated with oral GVHD).
astrointestinal Tract
Diagnostic features for the gastrointestinal (GI)
ract include esophageal web, stricture, or concentric rings
ocumented by endoscopy or barium contrast radio-
raph. Chronic GVHD may be associated with pan-
reatic exocrine insufﬁciency, which often improves
ith enzyme supplementation. Manifestations com-
on to both acute and chronic GVHD (as well as
ther causes, such as drug side effects, motility disor-
ers, infections, or malabsorption) include anorexia,
ausea, vomiting, diarrhea, weight loss, and failure to
ve
, but Insufficient
blish a
nic GVHD) Other Features*
Common
(Seen with Both Acute
and Chronic GVHD)
Thrombocytopenia
Eosinophilia
Lymphopenia
Hypo- or
hypergammaglobulinemia
Autoantibodies
(AIHA and ITP)
Pericardial or
pleural effusions
Ascites
Peripheral
neuropathy
Nephrotic
syndrome
Myasthenia gravis
Cardiac
conduction
abnormality or
cardiomyopathy
AST, aspartate aminotransferase; BOOP, bronchiolitis obliterans-
oimmune hemolytic anemia; ITP, idiopathic thrombocytopenic
the diagnosis is conﬁrmed.
excluded.
(or Schirmer test for eyes).istincti
GVHD
to Esta
f Chro
sferase;
A, aut
logy if
ust behrive. Wasting syndrome may be a manifestation of
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9hronic GVHD but is often multifactorial (e.g., de-
reased caloric intake, poor absorption, increased rest-
ng energy expenditures, and hypercatabolism). Endo-
copic ﬁndings of mucosal edema and erythema or
ocal erosions with histologic changes of apoptotic
pithelial cells and crypt cell dropout may be seen but
re not considered diagnostic of chronic GVHD un-
ess the patient also has distinctive features in a
on-GI system. Patients with unresolved acute
VHD may have more severe intestinal mucosal le-
ions, including ulcers and mucosal sloughing.
iver
Hepatic acute and chronic GVHD typically pre-
ents as cholestasis, with increased bilirubin or alkaline
hosphatase, but it may also present as acute hepatitis
21,22]. Because of many possible alternative diag-
oses, liver biopsy is required to conﬁrm GVHD
nvolvement of the liver. Note that because of the
istologic similarity between acute and chronic liver
VHD, the diagnosis of chronic GVHD cannot be
ade on the basis of liver biopsy alone but requires a
istinctive manifestation in at least 1 other organ sys-
em.
ungs
The only diagnostic manifestation of chronic
VHD is biopsy-proven BO. BO diagnosed via pul-
onary function and radiologic testing requires at
east 1 other distinctive manifestation in a separate
rgan system to establish the diagnosis of chronic
VHD. BO is characterized by the new onset of an
bstructive lung defect. Clinical manifestations may
nclude dyspnea on exertion, cough, or wheezing.
ome patients may be asymptomatic early in the dis-
ase process. Pneumothorax, pneumomediastinum,
nd subcutaneous emphysema are rare and often rep-
esent advanced disease. Restrictive pulmonary func-
ion abnormalities secondary to advanced sclerosis of
he chest wall are attributable to skin GVHD. BO is
linically diagnosed when all of the following criteria
re met:
. Forced expiratory volume in 1 second/forced vital
capacity ratio0.7 and forced expiratory volume in
1 second 75% of predicted.
. Evidence of air trapping or small airway thickening
or bronchiectasis on high-resolution chest com-
puted tomography (with inspiratory and expiratory
cuts), residual volume 120%, or pathologic con-
ﬁrmation of constrictive bronchiolitis.
. Absence of infection in the respiratory tract, doc-
umented with investigations directed by clinical
symptoms, such as radiologic studies (radiographs
or computed tomographic scans) or microbiologic
cultures (sinus aspiration, upper respiratory tract r
50viral screen, sputum culture, or bronchoalveolar
lavage).
. BO-organizing pneumonia not due to infections
may represent a manifestation of either acute or
chronic GVHD and is considered a common
feature.
usculoskeletal System
Diagnostic features include fascial involvement often
ffecting the forearms or legs and often associated with
clerosis of the overlying skin and subcutaneous tissue.
ascial involvement may develop without overlying scle-
otic changes of the skin and can result in joint stiffness or
ontractures when present near joints. Fasciitis is detected
n examination by stiffness, a restricted range of motion
e.g., often decreased dorsal wrist ﬂexion or inability to
ssume a Buddha prayer posture), edema of the extrem-
ties with or without erythema (early sign), peau d’orange
edematous skin with prominent pores resembling the
urface of an orange), or joint contractures (late complica-
ions). Clinical myositis with tender muscles and in-
reased muscle enzymes is a distinctive but nondiagnos-
ic manifestation of chronic GVHD. Myositis may
resent as proximal myopathy, but this complication is
are and does not explain the frequent complaints of
evere cramps. Evaluation of myositis involves electro-
yography and measurement of creatine phosphokinase
r aldolase. Arthralgia and arthritis are uncommon and
re occasionally associated with the presence of autoan-
ibodies.
ematopoietic and Immune Systems
Abnormalities are common in chronic GVHD but
annot be used to establish the diagnosis of chronic
VHD. Cytopenias may result from stromal damage
r autoimmune processes. Lymphopenia (500/L),
osinophilia (500/L), hypogammaglobulinemia, or
ypergammaglobulinemia may be present. Autoanti-
odies may develop with autoimmune hemolytic ane-
ia and idiopathic thrombocytopenic purpura.
hrombocytopenia (100 000/L) at the time of
hronic GVHD diagnosis has been associated with a
oor prognosis.
ther Findings
Serositis (pericardial or pleural effusions or as-
ites), peripheral neuropathy, myasthenia gravis, ne-
hrotic syndrome, and cardiac involvement have been
ttributed to chronic GVHD, but these manifesta-
ions are rare. For these manifestations, chronic
VHD is often a diagnosis of exclusion.
IFFERENTIAL DIAGNOSIS BETWEEN ACUTE AND
HRONIC GVHD
The Working Group recognized 2 main catego-
ies of GVHD, each with 2 subcategories (Table 2).
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Diagnosis and Staging of Chronic Graft-versus-Host Disease
Bhe broad category of acute GVHD includes (1) clas-
ic acute GVHD (maculopapular rash, nausea, vomit-
ng, anorexia, profuse diarrhea, ileus, or cholestatic
epatitis) occurring within 100 days after transplanta-
ion or DLI (without diagnostic or distinctive signs of
hronic GVHD) and (2) persistent, recurrent, or late
cute GVHD: features of classic acute GVHD with-
ut diagnostic or distinctive manifestations of chronic
VHD occurring beyond 100 days of transplantation
r DLI (often seen after withdrawal of immune sup-
ression). The broad category of chronic GVHD in-
ludes (1) classic chronic GVHD without features
haracteristic of acute GVHD and (2) an overlap syn-
rome in which features of chronic and acute GVHD
ppear together. In the absence of histologic or clin-
cal signs or symptoms of chronic GVHD, the persis-
ence, recurrence, or new onset of characteristic skin,
I tract, or liver abnormalities should be classiﬁed as
cute GVHD regardless of the time after transplanta-
ion. With appropriate stratiﬁcation, patients with
ersistent, recurrent, or late acute GVHD or overlap
yndrome can be included in clinical trials with pa-
ients who have chronic GVHD.
LINICAL SCORING OF ORGAN SYSTEMS
Figure 1 shows the consensus scoring system for
ndividual organs. Several considerations explain the
election of the features for the proposed scoring sys-
em versus the response criteria discussed in a separate
rticle. (1) Scoring criteria are intended for baseline or
ross-sectional use, whereas response criteria are in-
ended for serial use in therapeutic trials over a rela-
ively short period of time. (2) Scoring measures must
e designed so that they can be easily performed in the
fﬁce by general practitioners. By design, the only
equired laboratory testing needed to complete the
coring table is measurement of liver function. (3) The
road scoring categories help classify patients and
rovide immediate, clinically meaningful data about
he disease extent and severity. (4) The scoring system
oes not attempt to distinguish between disease activ-
ty and ﬁxed deﬁcits.
able 2. Categories of Acute and Chronic GVHD
Category
Time of
after H
cute GVHD
Classic acute GVHD <
Persistent, recurrent, or late-onset acute GVHD >
hronic GVHD
Classic chronic GVHD No ti
Overlap syndrome No ti
VHD indicates graft-versus-host disease; HCT, hematopoietic ce
See Table 1 for features.Organ sites considered for scoring include skin, o
B&MTouth, eyes, GI tract, liver, lungs, joints and fascia,
nd the female genital tract. Each organ or site is
cored according to a 4-point scale (0-3), with 0 rep-
esenting no involvement and 3 reﬂecting severe im-
airment. In addition, performance status is captured
n a 0 to 3 scale, and check boxes note the presence or
bsence of other speciﬁc manifestations.
Note that Figure 1 should be completed on the
asis of an assessment of current status without con-
ideration of past manifestations or a requirement for
ttribution of abnormalities to chronic GVHD versus
nother preexisting condition.
LOBAL SCORING OF CHRONIC GVHD
The time-honored description of limited versus
xtensive chronic GVHD was proposed from only 20
ases published in 1980 [2]. The Working Group
roposes a new global assessment of chronic GVHD
everity that is clinically suitable and is appropriate for
se as an inclusion criterion in therapeutic clinical
rials or as an indication for systemic immunosuppres-
ive treatment. The global scoring system reﬂects the
linical effect of chronic GVHD on the patient’s func-
ional status.
Elements included in the proposed global scoring
ystem include both the number of organs or sites
nvolved and the severity within each affected organ
note that performance status scoring is not incorpo-
ated into the global scoring system). The global de-
criptions of mild, moderate, and severe were chosen
o reﬂect the degree of organ impact and functional
mpairment due to chronic GVHD. Although scoring
s often used at the time of initial diagnosis, evaluating
he clinical score periodically during the course of
hronic GVHD may revise prognostic expectations
nd better describe the current severity of chronic
VHD. Note that the global scoring system can be
pplied only after the diagnosis of chronic GVHD is
onﬁrmed by either (1) the presence of a diagnostic
eature or, if a diagnostic feature is not present, (2) at
east 1 distinctive manifestation of chronic GVHD
ith the diagnosis supported by histologic, radiologic,
oms
DLI
Presence of Acute
GVHD Features*
Presence of Chronic
GVHD Features*
Yes No
Yes No
it No Yes
it Yes Yes
splantation; DLI, donor lymphocyte infusion.Sympt
CT or
100 d
100 d
me lim
me lim
ll tranr laboratory evidence of GVHD from any site.
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9SCORE 0 SCORE 1 SCORE 2 SCORE 3 
PERFORMANCE 
SCORE:
KPS   ECOG   LPS 
Asymptomatic 
and fully active 
(ECOG 0; KPS or 
LPS 100%) 
Symptomatic, 
fully ambulatory, 
restricted only in 
physically strenuous 
activity (ECOG 1, 
KPS or LPS 80-
90%) 
Symptomatic, 
ambulatory, 
capable of self-
care, >50% of 
waking hours out 
of bed (ECOG 2, 
KPS or LPS 60-
70%)  
Symptomatic, 
limited self-care, 
>50% of waking 
hours in bed (ECOG 
3-4, KPS or LPS 
<60%)
SKIN
Clinical features:
Maculopapular 
rash
Lichen planus-like 
features 
Papulosquamous 
lesions or ichthyosis 
Hyperpigmentation 
Hypopigmentation 
Keratosis pilaris 
Erythema 
Erythroderma  
Poikiloderma 
Sclerotic features  
Pruritus 
Hair involvement 
Nail involvement
% BSA  
involved
No Symptoms   <18% BSA with 
disease signs but 
NO sclerotic 
features 
19-50% BSA 
OR involvement 
with superficial 
sclerotic features 
“not hidebound” 
(able to pinch) 
>50% BSA OR
deep sclerotic 
features “hidebound” 
(unable to pinch) OR
impaired mobility, 
ulceration or severe 
pruritus 
MOUTH No symptoms  Mild symptoms 
with disease signs 
but not limiting oral 
intake significantly
Moderate 
symptoms with 
disease signs with
partial limitation of 
oral intake
Severe symptoms 
with disease signs on 
examination with
major limitation of 
oral intake
EYES
Mean tear test (mm): 
>10
6-10 
<5
Not done 
No symptoms  Mild dry eye 
symptoms not 
affecting ADL 
(requiring eyedrops 
< 3 x per day) OR
asymptomatic signs 
of  
keratoconjunctivitis 
sicca
Moderate dry 
eye symptoms 
partially affecting 
ADL (requiring 
drops > 3 x per day 
or punctal plugs), 
WITHOUT vision 
impairment 
Severe dry eye 
symptoms 
significantly 
affecting ADL 
(special eyeware to 
relieve pain) OR
unable to work 
because of ocular 
symptoms OR loss 
of vision caused by 
keratoconjunctivitis 
sicca
GI TRACT No symptoms Symptoms such 
as dysphagia, 
anorexia, nausea, 
vomiting, abdominal 
pain or diarrhea 
without significant 
weight loss (<5%) 
Symptoms 
associated with 
mild to moderate 
weight loss (5-
15%) 
Symptoms 
associated with 
significant weight 
loss >15%, requires 
nutritional 
supplement for most 
calorie needs OR
esophageal dilation 
LIVER Normal LFT Elevated 
Bilirubin, AP*, AST 
or ALT <2 x ULN 
Bilirubin >3 
mg/dl or Bilirubin, 
enzymes 2-5 x 
ULN  
Bilirubin or 
enzymes > 5 x ULN 
igure 1. Organ scoring of chronic GVHD. *AP may be elevated in growing children, and not reﬂective of liver dysfunction. †Pulmonary
coring should be performed using both the symptom and pulmonary function testing (PFT) scale whenever possible. When discrepancy exists
etween pulmonary symptom or PFT scores the higher value should be used for ﬁnal scoring. Scoring using the Lung Function Score (LFS)
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BSCORE 0 SCORE 1 SCORE 2 SCORE 3 
LUNGS†
FEV1
DLCO
No symptoms 
FEV1 > 80% OR
LFS=2
Mild symptoms 
(shortness of breath 
after climbing one 
flight of steps) 
FEV1 60-79% 
OR LFS 3-5 
Moderate 
symptoms 
(shortness of 
breath after 
walking on flat 
ground) 
 FEV1 40-59% 
OR LFS 6-9 
Severe symptoms 
(shortness of breath  
at rest; requiring 02)
 FEV1 <39% OR
LFS 10-12 
JOINTS AND 
FASCIA
No symptoms Mild tightness of 
arms or legs, normal 
or mild decreased 
range of motion 
(ROM) AND not 
affecting ADL
Tightness of 
arms or legs OR
joint contractures, 
erythema thought 
due to fasciitis, 
moderate decrease 
ROM AND mild to 
moderate limitation 
of ADL
Contractures 
WITH significant 
decrease of ROM
AND significant 
limitation of ADL 
(unable to tie shoes, 
button shirts, dress 
self etc.)
GENITAL TRACT No symptoms  Symptomatic with 
mild signs on exam 
AND no effect on 
coitus and minimal 
discomfort with 
gynecologic exam 
Symptomatic 
with moderate 
signs on exam 
AND with mild 
dyspareunia or 
discomfort with 
gynecologic exam 
Symptomatic 
WITH advanced 
signs (stricture, labial 
agglutination or 
severe ulceration) 
AND severe pain 
with coitus or 
inability to insert 
vaginal speculum 
Other indicators, clinical manifestations or complications related to chronic GVHD (check all that apply and 
assign a score to its severity (0-3) based on its functional impact where applicable (none – 0,mild -1, moderate 
-2, severe – 3)
Esophageal stricture or web___ Pericardial Effusion___  Pleural Effusion(s)___ 
Ascites (serositis)___  Nephrotic syndrome___  Peripheral Neuropathy___ 
M yasthenia Gravis___  Cardiomyopathy___  Eosinophilia > 500µl___ 
Polymyositis___                 Cardiac conduction defects___ Coronary artery involvement___ 
Platelets <100,000/µl ___  Progressive onset___ 
OTHERS:  Specify:_______________________________________________________________________________
igure 1 (continued). is preferred, but if DLCO is not available, grading using FEV1 should be used. The LFS is a global assessment of lung
unction after the diagnosis of bronchiolitis obliterans has already been established [29]. The percent predicted FEV1 and DLCO (adjusted
or hematocrit but not alveolar volume) should be converted to a numeric score as follows: 80%  1; 70-79%  2; 60-69%  3; 50-59%
4; 40-49%  5; 40%  6. The LFS  FEV1 score  DLCO score, with a possible range of 2-12. GVHD indicates graft versus host
isease; ECOG, Eastern Cooperative Oncology Group; KPS, Karnofsky Performance Status; LPS, Lansky Performance Status; BSA, body
urface area; ADL, activities of daily living; LFTs, liver function tests; AP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate
minotransferase; ULN, upper limit of normal.
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9Mild chronic GVHD involves only 1 or 2 organs or
ites (except the lung: see below), with no clinically sig-
iﬁcant functional impairment (maximum of score 1 in
ll affected organs or sites). Moderate chronic GVHD
nvolves (1) at least 1 organ or site with clinically signif-
cant but no major disability (maximum score of 2 in any
ffected organ or site) or (2) 3 or more organs or sites
ith no clinically signiﬁcant functional impairment
maximum score of 1 in all affected organs or sites). A
ung score of 1 will also be considered moderate chronic
VHD. Severe chronic GVHD indicates major disabil-
ty caused by chronic GVHD (score of 3 in any organ or
ite). A lung score of 2 or greater will also be considered
evere chronic GVHD.
NDICATIONS FOR SYSTEMIC THERAPY
Symptomatic mild chronic GVHD may often be
reated with local therapies alone (e.g., topical steroids
o the skin). However, in patients with chronic
VHD that involves 3 or more organs or with a score
f 2 or greater in any single organ, systemic immuno-
uppressive therapy may be considered. Good medical
ractice and judgment dictate ﬂexibility in this recom-
endation. Some experts incorporate the presence or
bsence of published high-risk features (e.g., throm-
ocytopenia) and the underlying reason for transplan-
ation (e.g., malignant versus nonmalignant underly-
ng disease) into the decision of whether or not to
reat with systemic immunosuppression. Early inter-
ention with effective systemic therapy may prevent
rogression to severe chronic GVHD, whereas co-
orbid infections may also modify decisions regard-
ng the timing and intensity of therapy. Effective im-
une modulating therapy given to patients with
linically signiﬁcant chronic GVHD involvement has
he potential to ameliorate the clinical manifestations,
educe TRM, or both. In patients who are already
eceiving immune-suppressive medications, the dos-
ge may be increased, or other agents can be added.
atients with chronic GVHD, especially those receiv-
ng systemic immunosuppressive therapy, are immu-
ocompromised and should receive infection-preven-
ion measures as outlined in the forthcoming Ancillary
herapy and Supportive Care Working Group docu-
ent.
SSESSMENT OF RISK OF TRM
Chronic GVHD is the major cause of late TRM
fter allogeneic HCT. Previous studies have identiﬁed
everal factors associated with an increased risk of
RM among patients with chronic GVHD, including
he involvement of multiple organs or sites, a de-
reased clinical performance score, thrombocytopenia
platelet count100 000/L) at the time of diagnosis, e
54rogressive onset of chronic GVHD from prior acute
VHD, hyperbilirubinemia, a higher percentage of
kin involvement at the time of diagnosis, and others
18,23-28]. Across studies, the characteristics consis-
ently associated with an increased risk of late TRM
mong patients with chronic GVHD are thrombocy-
openia and progressive onset of chronic GVHD from
cute GVHD.
Validation of risk factors for late TRM in patients
ith chronic GVHD should be a major goal of future
esearch, so that patients with the poorest prognoses
ill be included in clinical trials of systemic therapies
imed at changing the natural history of chronic
VHD. Conversely, patients judged at low risk for
RM might be preferentially enrolled in studies of
ew topical or organ-speciﬁc therapies. The standard-
zed approach for scoring chronic GVHD proposed
ere is suitable for use in future clinical studies to
valuate the extent to which the severity of speciﬁc
nd combined organ/site involvement correlates with
ate TRM in patients with chronic GVHD.
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